SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a

Blood

Volumn 112, Issue 5, 2008, Pages 2168-

  Seyfried, Irina ^a   Hofbauer, Sebastian ^a   Stoecher, Markus ^a   Greil, Richard ^a   Tinhofer, Inge ^a  

^a St Johanns Spital   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

NUTLIN 3; PROTEIN P53; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; MDM2 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PROTEIN MDM2;

B CELL LYMPHOMA; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HUMAN; LETTER; LEUKEMIA CELL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; B CELL LEUKEMIA; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; IN VITRO STUDY; NOTE; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

ALLELES; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENES, P53; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 52649119010     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-158634     Document Type: Letter

References (8)

1. Saddler C, Ouillette P. Kujawski L et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood. 2008;111:1584-1593.
2. Gryshchenko I, Hofbauer S, Stoecher M, et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol. 2008; 26:2252-2257.
3. Bond GL, Hu W, Bond EE. et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591-602.
4. Coll-Mulet L. Iglesias-Serret D, Santidrian AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood. 2006;107:4109-4114.
5. Secchiero P. Barbarotto E, Tiribelli M. et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2006;107: 4122-4129.
6. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood. 2006;108: 993-1000.
7. Kojima K. Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106: 3150-3159.
8. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A. 2006:103:1888-1893.